Seagen v Daiichi Sankyo (Fed. Cir., December 2, 2025) 2023-2424
This episode presents an opinion from the United States Court of Appeals for the Federal Circuit, resolving a patent dispute between Seagen Inc. and Daiichi Sankyo Company, Ltd. concerning an antibody-drug conjugate (ADC) cancer treatment. Seagen had previously secured a jury verdict in the Eastern District of Texas finding that Daiichi's drug, Enhertu®, willfully infringed the ’039 patent and awarded Seagen over $41 million in damages. However, the Federal Circuit reversed the district court’s denial of judgment as a matter of law (JMOL), finding the ’039 patent to be invalid. The court…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.